CA3043619A1 - Albumin-binding psma inhibitors - Google Patents

Albumin-binding psma inhibitors Download PDF

Info

Publication number
CA3043619A1
CA3043619A1 CA3043619A CA3043619A CA3043619A1 CA 3043619 A1 CA3043619 A1 CA 3043619A1 CA 3043619 A CA3043619 A CA 3043619A CA 3043619 A CA3043619 A CA 3043619A CA 3043619 A1 CA3043619 A1 CA 3043619A1
Authority
CA
Canada
Prior art keywords
compound
formula
independently
active
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3043619A
Other languages
English (en)
French (fr)
Inventor
Clifford BERKMAN
Cindy CHOY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Targeted Technology LLC
Original Assignee
Cancer Targeted Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Technology LLC filed Critical Cancer Targeted Technology LLC
Publication of CA3043619A1 publication Critical patent/CA3043619A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/08—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with two six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3043619A 2016-11-23 2017-11-24 Albumin-binding psma inhibitors Pending CA3043619A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425810P 2016-11-23 2016-11-23
US62/425,810 2016-11-23
PCT/US2017/063182 WO2018098390A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Publications (1)

Publication Number Publication Date
CA3043619A1 true CA3043619A1 (en) 2018-05-31

Family

ID=60812130

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043619A Pending CA3043619A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Country Status (8)

Country Link
US (1) US11147889B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544960A1 (cg-RX-API-DMAC7.html)
JP (1) JP7167021B2 (cg-RX-API-DMAC7.html)
CN (1) CN109982998A (cg-RX-API-DMAC7.html)
BR (1) BR112019010206A2 (cg-RX-API-DMAC7.html)
CA (1) CA3043619A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019005742A (cg-RX-API-DMAC7.html)
WO (1) WO2018098390A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
US20210276971A1 (en) * 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
WO2020102348A1 (en) 2018-11-14 2020-05-22 Stephen Dimagno Thioamide-containing compositions and methods of use thereof
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
AU2020257786B2 (en) 2019-04-17 2025-10-23 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
BR112021025810A2 (pt) 2019-06-21 2022-05-10 Provincial Health Services Authority Compostos radiomarcados direcionando o antígeno de membrana específico da próstata
AU2021230210A1 (en) 2020-03-04 2022-09-22 Kyoto University Compound and radioactive labeling compound
AU2021267477A1 (en) * 2020-05-06 2022-12-01 Cornell University Copper-containing theragnostic compounds and methods of use
AU2021390552A1 (en) * 2020-12-04 2023-06-29 The Regents Of The University Of California Peptide receptor radionuclide therapy
EP4263509A4 (en) * 2020-12-16 2024-12-04 The University of British Columbia RADIOACTIVELY LABELLED COMPOUNDS FOR TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
AU2022228911A1 (en) 2021-03-04 2023-09-21 Kyoto University Compound and radioactive labeling compound
CN116940557A (zh) * 2021-03-04 2023-10-24 日本医事物理股份有限公司 化合物及放射性标记化合物
CA3244865A1 (en) * 2022-03-04 2023-09-07 Provincial Health Services Authority RADIOLABELLED COMPOUNDS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety
WO2024169037A1 (zh) * 2023-02-16 2024-08-22 无锡诺宇医药科技有限公司 Psma靶向放射性药物及其合成和应用
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US9056841B2 (en) 2009-03-19 2015-06-16 The Johns Hopkins University PSMA-targeting compounds and uses thereof
AU2012294639B2 (en) 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
EP3066105A4 (en) * 2013-11-06 2017-10-11 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
EP3533473A3 (en) * 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
EP3183236B1 (en) * 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
KR102233726B1 (ko) 2015-09-30 2021-03-31 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도
RS65188B1 (sr) * 2016-03-22 2024-03-29 Univ Johns Hopkins Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate
CN109843339B (zh) * 2016-06-23 2023-07-07 康奈尔大学 影响肿瘤杀伤的双重靶向构建体
DE102016122273B4 (de) 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung

Also Published As

Publication number Publication date
BR112019010206A2 (pt) 2019-09-03
US11147889B2 (en) 2021-10-19
EP3544960A1 (en) 2019-10-02
CN109982998A (zh) 2019-07-05
JP2019535754A (ja) 2019-12-12
MX2019005742A (es) 2019-09-13
US20200061218A1 (en) 2020-02-27
JP7167021B2 (ja) 2022-11-08
WO2018098390A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
CA3043619A1 (en) Albumin-binding psma inhibitors
AU2023203682B2 (en) Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
TWI657827B (zh) 用於正子斷層掃描之化合物
ES2657863T3 (es) Inhibidores quelados de PSMA
AU2022219525B2 (en) Bivalent fibroblast activation protein ligands for targeted delivery applications
JP7529735B2 (ja) キレート化されたｐｓｍａ阻害剤
BR112012001260B1 (pt) Conjugados de épsilon-polilisina, seu uso, conjugado de macromolécula, e kit
TR201808820T4 (tr) Nükleer görüntüleme ve radyoterapi için şelatörlerin etkili sentezi: bileşimler ve uygulamalar.
JP7646637B2 (ja) 画像化及び治療用組成物
AU2021427618B2 (en) Truncated evans blue modified fibroblast activation protein inhibitor, preparation method therefor, and application thereof
AU2017318087A1 (en) Amino mercaptan compound and preparation method therefor and use thereof in protection against radiation
CA3205844A1 (en) Ligands and their use
CN116217505A (zh) 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
US11191778B2 (en) Multifunctional linker technology containing an N4 group
US10286090B2 (en) Targeted contrast agents comprising a hydrazide functional group
JPH06504273A (ja) キレート剤
WO2005028490A1 (en) Halogenated deoxy-glucose labeled targeting molecules
CN111263768B (zh) 抗癌肽
JP2020517584A (ja) 修飾ｍｒｉ造影剤およびその使用
US20220072165A1 (en) Radiodrug for diagnostic/therapeutic use in nuclear medicine and radio-guided medicine
BR112023015831B1 (pt) Ligantes de proteína de ativação de fibroblastos bivalentes para aplicações de liberação direcionada, composições farmacêuticas, seus usos e métodos para preparar um conjugado
JP2024518097A (ja) 刷子縁膜酵素切断可能リンカーを持つ葉酸受容体標的コンジュゲート並びにガンのイメージング及び治療における使用方法
CN121226334A (zh) 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用
IL323763A (en) Antibody-drug conjugates of camptothecin derivatives and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220620

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20241015

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251111